# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. 2)\*

## **Deciphera Pharmaceuticals, Inc.**

(Name of Issuer)

#### **Common Stock**

(Title of Class of Securities)

#### 24344T101

(CUSIP Number)

#### December 31, 2023

(Date of Event which Requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Notes).

any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

	Rule 13d-1(b)	
	Rule 13d-1(c) Rule 13d-1(d)	
* T	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities	and f

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the

	CUSIF	No. 2	4344T101	Schedule 13G	Page 2 of 5 Pages
1 Na	mes of Re	eportin	g Persons		
Br	ightstar A	Associa	ntes LLC		
			iate Box if a Member of a	Group	(a) [ ]
					(b) [ ]
3 SE	EC Use On	ıly			
4 Cit	tizen or Pl	ace of	Organization		
Mi	issouri				
		5	Sole Voting Power		
			23,059,708		
Number of	Charac	6	Shared Voting Power		
Beneficially	y Owned		0		
by Each Rep Person With	ch Reporting	7	Sole Dispositive Powe	r	
Person With	n		·		
		0	23,059,708		
		8	Shared Dispositive Pov	wer	
			0		
9 Ag	ggregate A	mount	Beneficially Owned by E	ach Reporting Person	
23.	,059,708				
		Aggre	gate Amount in Row (9) E	Excludes Certain Shares	[]
11 Per	roont of a	Class I	Represented by Amount in	Day 0	
11 FC	iceni oi a	Class I	Represented by Amount in	ROW 9	
	.2%				
12 Ty	Type of Reporting Person				
Liı	mited Lia	bility	Company		

CUSIP No. 24344T101	Schedule 13G	Page 3 of 5 Pages
---------------------	--------------	-------------------

#### ITEM 1. (a) Name of Issuer:

Deciphera Pharmaceuticals, Inc. (the "Issuer").

#### (b) Address of Issuer's Principal Executive Offices:

200 Smith Street, Waltham, MA 02451

#### ITEM 2. (a) Name of Person Filing:

This statement is filed on behalf of Brightstar Associates LLC (the "Reporting Person").

#### (b) Address or Principal Business Office:

The business address of the Reporting Person is 1020 Central Street, Suite 300, Kansas City, Missouri 64105.

#### (c) Citizenship of each Reporting Person is:

The Reporting Person is incorporated in the State of Missouri.

#### (d) Title of Class of Securities:

Common Stock, par value \$0.01 per share (the "Common Stock").

#### (e) CUSIP Number:

24344T101

#### ITEM 3.

Not applicable.

## ITEM 4. Ownership

The ownership information presented below represents beneficial ownership of shares of Common Stock of the Issuer as of the date of this filing, based upon 80,800,062 shares of Common Stock outstanding as of January 31, 2024, as disclosed in the Issuer's annual report on Form 10-K as filed with the Securities and Exchange Commission on February 6, 2024.

## (a) Amount beneficially owned:

The Reporting Person is the record holder of 23,059,708 shares of Common Stock and a currently exercisable warrant for the purchase of up to an additional 48,136 shares of Common Stock. The warrant contains a limitation on exercise that provides that the warrant may not be exercised to the extent that it would cause the Reporting Person to beneficially own more than 28.22% of the then-outstanding Common Stock.

CUSIP No. 24344T101	Schedule 13G	Page 4 of 5 Pages
---------------------	--------------	-------------------

The Reporting Person is managed by a three-person managing board consisting of Greg A. Hamilton, Mark K. Fallon, and Timothy Fritzel, and all action relating to the voting or disposition of these shares requires approval of a majority of the board. Such individuals expressly disclaim any beneficial ownership over the shares held by the Reporting Person.

## (b) Percent of class: 28.2%

## (c) Number of shares as to which the person has:

- (i) Sole power to vote or to direct the vote: 23,059,708
- (ii) Shared power to vote or direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 23,059,708
- (iv) Shared power to dispose or to direct the disposition of: 0

#### ITEM 5. Ownership of Five Percent or Less of a Class

Not applicable.

## ITEM 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

## ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

## ITEM 8. Identification and Classification of Members of the Group

Not applicable.

## ITEM 9. Notice of Dissolution of Group

Not applicable.

#### ITEM 10. Certification

Not applicable.

CUSIP No. 24344T101	Schedule 13G	Page 5 of 5 Pages
---------------------	--------------	-------------------

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 9, 2024

## **Brightstar Associates LLC**

By: /s/ Greg A. Hamilton
Name: Greg A. Hamilton

Title: Member of the Board of Managers